PpProf. Peptide
← Back to Supplement Library

Alpha Lipoic Acid

Metabolic & Weight Loss

Last reviewed: May 26, 2026

Also Known As: ALA, thioctic acid, lipoic acid, R-ALA (bioactive stereoisomer), Na-R-ALA / sodium R-lipoate (stabilized R-ALA)

Supplement Class: Organosulfur compound / universal antioxidant (fat + water soluble) / AMPK activator / mitochondrial enzyme cofactor (pyruvate dehydrogenase, α-ketoglutarate dehydrogenase)

Evidence Tier: Strong — ALADIN study (Ziegler 1995, n=328) + Mijnhout 2012 meta-analysis (15 RCTs) for diabetic peripheral neuropathy (approved as medical treatment in Germany); Jacob 1999 hyperinsulinemic-euglycemic clamp for insulin sensitization; Namazi 2018 meta-analysis (12 RCTs) for modest weight loss; Zhang 2011 for metabolic syndrome biomarkers

What is alpha lipoic acid?

Alpha lipoic acid (ALA) is a naturally occurring organosulfur compound produced in small amounts by the body and found in trace amounts in red meat, spinach, and broccoli. Its supplement profile is built on a unique combination: it's a universal antioxidant active in both fat-soluble and water-soluble environments (unusual — most antioxidants work in only one), it activates AMPK (the same metabolic master switch metformin and berberine target), it's a mitochondrial enzyme cofactor for pyruvate dehydrogenase and α-ketoglutarate dehydrogenase, and it regenerates other antioxidants (vitamins C, E, glutathione, CoQ10) back to their active forms. The most clinically validated application is diabetic peripheral neuropathy — ALA is approved as medical treatment in Germany and other European countries based on the ALADIN study (Ziegler 1995) and subsequent meta-analyses (Mijnhout 2012). Secondary evidence supports insulin sensitization (Jacob 1999 hyperinsulinemic-euglycemic clamp showed 27% glucose-disposal improvement), modest weight loss (Namazi 2018 meta-analysis), and anti-inflammatory effects in metabolic syndrome. The practical considerations are stereoisomer choice (R-ALA is ~12× more bioavailable than racemic S-ALA half) and empty-stomach timing (food reduces absorption by ~30%). ALA pairs naturally with mitochondrial peptides like MOTS-c and NAD+ peptide — overlapping AMPK and cofactor mechanisms at different signaling layers.

Reported benefits:

  • Significant diabetic peripheral neuropathy symptom reduction (ALADIN study, Mijnhout 2012 meta-analysis — European medical approval)
  • Insulin sensitization (27% glucose-disposal improvement per Jacob 1999 clamp methodology)
  • Modest weight loss (-1.52 kg average per Namazi 2018 meta-analysis, 12 RCTs)
  • Reduced inflammatory markers (TNF-α, IL-6, CRP) in metabolic syndrome (Zhang 2011)
  • Universal antioxidant activity across fat-soluble and water-soluble cellular compartments
  • Regenerates oxidized vitamin C, vitamin E, glutathione, CoQ10 back to active forms
  • AMPK activation (same mechanism class as metformin and berberine)
  • Mitochondrial enzyme cofactor for pyruvate dehydrogenase and α-ketoglutarate dehydrogenase

Common dose: 300–600 mg/day stabilized R-ALA (Na-R-ALA / sodium R-lipoate) for metabolic/antioxidant baseline; 600–1,200 mg/day racemic ALA as cheaper alternative. For diabetic neuropathy: 600–1,800 mg/day oral, split AM + PM + lunch, for 4–8 weeks minimum (coordinate with clinician). Take 30–60 minutes before meals — food reduces absorption by ~30%.

Watch for: Hypoglycemia when combined with metformin / sulfonylureas / insulin / GLP peptides — monitor glucose. Biotin competition over chronic long-term use (6+ months at 600+ mg/day) — add standard B-complex as buffer.

Shop Alpha Lipoic Acid on Amazon →

How does alpha lipoic acid work?

Alpha lipoic acid works through multiple parallel mechanisms — universal antioxidant activity (fat and water soluble, regenerates other antioxidants), AMPK activation (overlapping with metformin and berberine), mitochondrial cofactor activity (pyruvate dehydrogenase and α-ketoglutarate dehydrogenase complexes), and nerve-tissue protection. The combination is what makes it uniquely effective for diabetic neuropathy where multiple of these pathways converge.

  1. Universal antioxidant — fat AND water soluble. ALA's small molecular size and disulfide bond structure make it active in both lipid membranes and aqueous cellular compartments — unusual for an antioxidant. It directly scavenges hydroxyl radicals, hypochlorous acid, singlet oxygen, and peroxynitrite. This comprehensive antioxidant coverage distinguishes ALA from vitamin C (water-soluble only) or vitamin E (fat-soluble only).
  2. Antioxidant regeneration network. ALA regenerates oxidized forms of vitamin C, vitamin E, glutathione, and CoQ10 back to their active reduced forms. This amplifies the effective antioxidant capacity of the entire endogenous antioxidant network, not just ALA's own free-radical scavenging.
  3. AMPK activation. ALA activates AMP-activated protein kinase, the master metabolic switch that improves insulin sensitivity, increases glucose uptake in muscle and fat, and reduces hepatic gluconeogenesis. This is the same mechanism class as metformin and berberine, and the basis for ALA's metabolic and weight-loss effects.
  4. Mitochondrial enzyme cofactor. ALA is an essential cofactor for pyruvate dehydrogenase and α-ketoglutarate dehydrogenase — two key enzymes in the citric acid cycle that connect glycolysis to mitochondrial energy production. Supplementation supports the efficiency of this energy-conversion machinery, particularly in tissues with high mitochondrial demand.
  5. Nerve tissue protection. In diabetic peripheral neuropathy, ALA reduces oxidative stress in nerve tissue, improves nerve conduction velocity, and reduces hyperglycemia-induced microvascular damage to peripheral nerves. This is the most clinically validated ALA application, with multiple European RCTs and a meta-analysis supporting the use case.
  6. Anti-inflammatory effects. ALA reduces NF-κB activation and downstream inflammatory cytokines (TNF-α, IL-6, CRP). This is mechanistically secondary to the antioxidant arm but contributes to ALA's effects in metabolic syndrome and chronic-inflammation contexts.

What does alpha lipoic acid actually do?

ALA has one of the deeper European medical-supplement evidence bases. Strongest evidence is for diabetic peripheral neuropathy (IV and oral RCTs + meta-analyses); moderate evidence for insulin sensitivity and modest weight loss; emerging evidence for inflammation and metabolic syndrome adjunct.

  1. Diabetic peripheral neuropathy (Strong). ALADIN study (Ziegler 1995, n=328) established IV ALA at 600 mg/day for 3 weeks produces significant Total Symptom Score reduction. Mijnhout 2012 meta-analysis (15 RCTs) confirms oral ALA at 600–1,800 mg/day for 3–5 weeks produces moderate but consistent symptom relief. This is the European medical-approval indication.
  2. Insulin sensitivity (Strong-Moderate). Jacob 1999 used hyperinsulinemic-euglycemic clamp (gold standard) to demonstrate 27% improvement in glucose disposal with 600 mg twice daily oral ALA in T2D patients. Multiple subsequent trials confirm the insulin-sensitization effect.
  3. Body weight reduction (Moderate). Namazi 2018 meta-analysis (12 RCTs, n=634) found ALA produced statistically significant weight reduction (-1.52 kg average), with greater effect at 1,200+ mg/day. Modest but real; AMPK-mediated mechanism overlaps with metformin and berberine.
  4. Inflammatory marker reduction (Moderate). Zhang 2011 and others document TNF-α, IL-6, CRP reductions in metabolic syndrome patients with ALA supplementation. Anti-inflammatory effect is consistent across trials.
  5. Glucose control in T2D (Moderate). HbA1c and fasting glucose reductions documented in multiple trials, particularly when combined with metformin or other glucose-lowering medications.
  6. Cognitive function in MS / cognitive aging (Emerging). Some trials suggest cognitive function preservation in multiple sclerosis and modest improvements in cognitive aging populations. Evidence base is thinner than the neuropathy/metabolic case.
  7. Autonomic neuropathy (Moderate). Cardiac autonomic neuropathy in diabetics shows symptomatic improvement in some trials. Useful clinical indication beyond peripheral neuropathy.
  8. Liver disease (Emerging). NAFLD and metabolic-associated steatotic liver disease trials show some hepatoprotective signal. Evidence is preliminary.

How is alpha lipoic acid dosed?

ALA dosing depends on goal and form. For metabolic / antioxidant baseline: 300–600 mg/day R-ALA (or 600–1,200 mg/day racemic ALA). For diabetic neuropathy: 600–1,800 mg/day oral (typically split as 600 mg twice or three times daily). For weight loss: higher doses (1,200–1,800 mg/day) per Namazi 2018 dose-response. Always 30–60 minutes before meals for optimal absorption.

  1. Metabolic / antioxidant baseline (R-ALA). 300–600 mg/day stabilized R-ALA (Na-R-ALA / sodium R-lipoate), split AM + PM, on empty stomach.
  2. Metabolic / antioxidant baseline (racemic ALA). 600–1,200 mg/day racemic ALA — roughly 2× the R-ALA dose due to lower bioavailability of the S-ALA half.
  3. Diabetic neuropathy (oral). 600 mg two or three times daily (1,200–1,800 mg/day total), 30 minutes before meals, for 4–8 weeks minimum. Coordinate with prescribing clinician — often combined with B-vitamins for comprehensive neuropathy protocol.
  4. Weight loss adjunct. 1,200–1,800 mg/day per Namazi 2018 meta-analytic dose-response. The effective range for the meta-analytic effect.
  5. IV ALA (medical only). 600 mg/day infusion for 3 weeks — the ALADIN protocol. Used in European clinical practice for diabetic neuropathy; not self-administered.

Timeline: neuropathy effects 4–8 weeks (faster for IV); insulin sensitivity 4–6 weeks; weight loss 8–12 weeks. ALA is a chronic-use supplement — antioxidant and AMPK effects build over weeks.

Label math. “Alpha lipoic acid 600 mg” usually means racemic ALA (300 mg R-ALA + 300 mg less-active S-ALA). “R-ALA 300 mg” or “Na-R-ALA / sodium R-lipoate 300 mg” means 300 mg of the active stereoisomer — roughly equivalent to 600 mg racemic. Read for the form explicitly.

How to take alpha lipoic acid

ALA is taken orally as capsules or tablets. The two practical considerations are empty-stomach timing (food reduces absorption by ~30%) and form choice (R-ALA vs racemic). The points below cover the details experienced users converge on.

AspectRecommendation
FrequencyTwice daily for baseline use; three times daily for higher-dose neuropathy protocols. Split dosing maintains steadier antioxidant coverage.
Best time of day30–60 minutes before meals (empty stomach) — food reduces absorption by up to 30%. Morning before breakfast + 30 min before lunch or dinner is the practical default.
FoodEmpty stomach preferred — competes with dietary amino acids for transporter-mediated gut absorption. If GI upset, small low-protein snack OK.
FormR-ALA (R-alpha lipoic acid) or stabilized Na-R-ALA (sodium R-lipoate) — the bioactive stereoisomer, ~12× more bioavailable than S-ALA. Racemic ALA (50/50 R+S) is cheaper but less efficient. Avoid pure S-ALA (essentially inactive).
Standardization markerLook for “R-ALA,” “R-alpha lipoic acid,” or “Na-R-ALA / sodium R-lipoate” explicitly — these denote the bioactive stereoisomer. “Alpha lipoic acid” without R/S designation is typically racemic (50/50). Third-party tested for stereoisomer purity is the relevant screen.
Cycling / B-vitamin pairingFor chronic long-term use (6+ months at 600+ mg/day), add a standard B-complex or 30–100 mcg biotin daily to offset ALA's competitive biotin uptake. Not required for shorter courses.

What does alpha lipoic acid stack with?

ALA pairs naturally with the broader mitochondrial bioenergetics and metabolic toolkit. The mechanism spans antioxidant, AMPK activation, and mitochondrial cofactor activity — which complements peptides operating on mitochondrial biogenesis, NAD+ supply, and broader metabolic peptide protocols. The three areas below cover the natural stacking categories.

With peptides

ALA pairs naturally with the mitochondrial peptide cluster. MOTS-c is a mitochondrial-derived peptide that activates AMPK, improves insulin sensitivity, and supports mitochondrial biogenesis at the genetic/regulatory level — direct mechanism overlap with ALA's AMPK arm but at a different layer (peptide-level signaling vs small-molecule modulator). NAD+ peptide delivers NAD+ — the cofactor for sirtuins and the electron donor for Complex I of the electron transport chain. ALA operates at multiple layers: AMPK activation, mitochondrial enzyme cofactor activity (pyruvate dehydrogenase, α-ketoglutarate dehydrogenase), universal antioxidant protection of mitochondrial membranes, and regeneration of CoQ10/glutathione/vitamins C and E. The three converge on mitochondrial bioenergetics from different angles — MOTS-c on biogenesis signaling, NAD+ peptide on cofactor supply, ALA on cofactor activity + antioxidant protection. Mechanistically additive, no known negative interactions. For users on GLP-1 peptides ( semaglutide, tirzepatide ), ALA is a compatible metabolic adjunct that adds AMPK-mediated insulin-sensitization to the GLP receptor-agonist mechanism.

With supplements

  1. CoQ10 — ALA regenerates oxidized CoQ10 back to its active form. Mechanistically natural pairing for mitochondrial protection.
  2. Berberine — additional AMPK activator with metformin-comparable glycemic effects. Common metabolic-stack co-occupant; complementary AMPK activation.
  3. Chromium — insulin-receptor amplification via chromodulin. Different mechanism from ALA's AMPK activation; complementary glycemic support.
  4. Magnesium — cofactor for hundreds of enzymes including glucose metabolism. Deficiency correction supports the system ALA operates within.
  5. Vitamin C — ALA regenerates oxidized vitamin C; complementary antioxidant network.
  6. Biotin (30–100 mcg daily) — offsets ALA's competitive biotin uptake over chronic long-term use. Add B-complex for comprehensive coverage.
  7. B1 (benfotiamine) — particularly relevant for diabetic neuropathy stacks; benfotiamine is a fat-soluble B1 derivative that complements ALA's neuroprotective effects.

With lifestyle

  1. 30 minutes before meals. Empty-stomach absorption is meaningfully better. Plan dosing around meal timing.
  2. Glucose monitoring during dose titration. Particularly relevant if combining with metformin, sulfonylureas, insulin, berberine, or GLP peptides. Hypoglycemia risk during the first 4–6 weeks of combined use.
  3. B-vitamin supplementation for chronic use. Long-term high-dose ALA may compete with biotin uptake; standard B-complex or 30–100 mcg biotin daily is a low-cost mitigation.
  4. Resistance training and aerobic exercise. Exercise independently activates AMPK; ALA + exercise produces additive mitochondrial benefit.
  5. Whole-foods anti-inflammatory diet. ALA works on top of dietary foundation. Mediterranean-style eating supports the metabolic and antioxidant context ALA operates within.

Side effects and interactions

ALA has a favorable safety profile at standard supplemental doses. The main practical considerations are GI effects, hypoglycemia risk when combined with diabetes medications, biotin-competition over chronic use, and rare skin/allergic reactions.

Common (mostly transient)

  1. Mild GI discomfort — nausea, abdominal pain, particularly on empty stomach. Resolves with small low-protein snack if needed.
  2. Garlic / sulfur-like body odor — ALA is an organosulfur compound; some users report mild distinctive odor.
  3. Headache — occasional, generally mild and dose-related.
  4. No documented serious adverse events at standard supplemental doses across the human RCT base.

Less common (watch-list)

  1. Hypoglycemia — when combined with insulin, sulfonylureas, metformin, GLP peptides, or other glucose-lowering supplements. Monitor glucose during titration.
  2. Biotin competition — chronic long-term ALA (6+ months at 600+ mg/day) may reduce biotin status via competitive transporter uptake. Add standard B-complex as buffer.
  3. Thiamine deficiency in malnourished users — ALA's mitochondrial enzyme cofactor activity competes with thiamine. Rare; relevant in alcoholic or malnourished populations.
  4. Skin rash or allergic reactions — rare; discontinue if persistent.
  5. Insulin autoimmune syndrome — very rare; mostly reported in Asian populations with specific HLA genotypes.

Drug and supplement interactions

  1. Diabetes medications (metformin, sulfonylureas, insulin). Additive glucose-lowering. Monitor glucose; clinician may adjust diabetes medication doses.
  2. GLP-1 peptides (semaglutide, tirzepatide). Compatible; mechanistically additive on insulin sensitivity. Watch hypoglycemia if also on sulfonylureas/insulin.
  3. Thyroid medication (levothyroxine). ALA may modestly affect thyroid hormone metabolism at high doses; coordinate with prescribing clinician.
  4. Chemotherapy — ALA may affect some chemotherapy regimens via antioxidant interference with treatment-induced oxidative damage. Coordinate with oncologist.
  5. Heavy metal chelation — ALA has mild chelation activity. Don't use in conjunction with active mercury/lead chelation therapy without specialist guidance.
  6. Pregnancy and breastfeeding — insufficient supplemental-dose data; defer to clinician.

What we don't know yet about alpha lipoic acid

ALA has solid European medical-supplement evidence in diabetic neuropathy, but several open questions affect how confidently it can be recommended for broader use cases.

R-ALA vs racemic head-to-head outcomes. R-ALA is ~12× more bioavailable per gram, but most large clinical trials used racemic ALA at higher gram-equivalents. Whether R-ALA at lower doses produces equivalent clinical outcomes is mechanistically plausible but not rigorously head-to-head RCT-tested at scale.

Healthy young-adult metabolic transfer. The strongest evidence is in T2D, diabetic neuropathy, metabolic syndrome, and insulin-resistant populations. Whether ALA produces meaningful benefit in metabolically healthy adults under 40 is less directly supported by trial data.

Long-term high-dose safety. Most trial data extends to 8–12 weeks at 600–1,800 mg/day. Multi-year continuous use at the higher doses is not characterized in controlled trials — though the safety profile of moderate dosing is reassuring.

Biotin competition clinical significance. Mechanism is documented; clinical relevance over multi-year use isn't well-quantified. Standard mitigation (add B-complex) is low-cost; whether all chronic users need it isn't precisely known.

Cognitive and neurodegenerative applications. Preclinical evidence is encouraging for Alzheimer's, Parkinson's, multiple sclerosis; human RCT outcomes have been mixed. Whether higher doses or different formulations would produce reliable cognitive benefit is open.

Insulin autoimmune syndrome risk in Asian populations. Rare case reports of insulin autoimmune syndrome in Asian users with specific HLA genotypes. Risk magnitude isn't well-characterized; relevant for users of East Asian descent.

Weight-loss clinical significance. Namazi 2018 meta-analytic effect is statistically significant (-1.52 kg) but small in absolute terms. Whether ALA adds meaningfully to weight-loss protocols already employing GLP peptides or other established interventions is unclear.

Where to buy alpha lipoic acid

Alpha lipoic acid is widely available over-the-counter. Quality varies — particularly around stereoisomer disclosure (R-ALA vs racemic vs S-ALA), stabilization (R-ALA without sodium stabilization degrades quickly), and source authentication. The screen below is what we use before clicking through.

Quality markers to look for

  • Stabilized R-ALA (Na-R-ALA / sodium R-lipoate) — the bioactive stereoisomer in its shelf-stable form. ~12× more bioavailable than S-ALA.
  • Or racemic ALA as cheaper option — accept lower per-mg efficiency. Adjust dose upward (~2× R-ALA dose).
  • Stereoisomer explicitly disclosed — “R-ALA,” “R-alpha lipoic acid,” “Na-R-ALA,” or “sodium R-lipoate.” Avoid plain “alpha lipoic acid” products that don't disclose stereoisomer composition.
  • Third-party tested — USP, NSF, or ConsumerLab certifications signal independent verification. HPLC verification of stereoisomer purity is the relevant test.
  • cGMP-certified manufacturing facility — minimum bar for any supplement.
  • No proprietary blends that obscure the actual ALA dose or stereoisomer composition alongside fillers.
  • Fresh manufacture date — unstabilized R-ALA degrades with heat and humidity; avoid jars sitting on warehouse shelves >12 months. Na-R-ALA is more stable.
  • Capsule preferred over powder for ALA — encapsulation protects from oxidation and moisture.
Shop Alpha Lipoic Acid on Amazon →

Amazon affiliate link — Prof. Peptide earns a small commission on qualifying purchases at no extra cost to you. We use commissions to fund research and editorial work.

Alpha Lipoic Acid FAQ

R-ALA vs racemic ALA — which form should I take?

R-ALA (R-alpha lipoic acid) is the naturally occurring stereoisomer and roughly 12× more bioavailable than the unnatural S-ALA enantiomer. Standard racemic ALA is a 50/50 mixture of R-ALA + S-ALA — the S-ALA half is essentially inert and may even compete with R-ALA absorption. For equivalent serum R-ALA: 200–300 mg R-ALA ≈ 600 mg racemic ALA. Practical default: stabilized R-ALA (Na-R-ALA / sodium R-lipoate) at 300–600 mg/day for metabolic/antioxidant use. Standard racemic ALA at 600–1,200 mg/day is acceptable budget option but less efficient. R-ALA is what the European diabetic neuropathy clinical use is built on.

Why take alpha lipoic acid on an empty stomach?

Food reduces ALA absorption by up to 30% because ALA competes with dietary amino acids for transporter-mediated gut absorption. The conservative protocol: 30–60 minutes before meals, twice daily. Practical version: take morning dose 30 minutes before breakfast; second dose 30+ minutes before lunch or dinner. The empty-stomach effect is real but not catastrophic — if you can only take ALA with food, take it with the lowest-protein meal. Some users report mild GI discomfort on empty stomach; resolves with smaller doses or split timing.

Does ALA actually help diabetic neuropathy?

Yes — and it's actually approved for this indication in Germany and other European countries. Multiple RCTs and meta-analyses (Ziegler 1995, Ziegler 2006, Mijnhout 2012) demonstrate ALA significantly reduces neuropathy symptoms (pain, burning, numbness, paresthesia) in diabetic peripheral neuropathy. Intravenous ALA (600 mg/day for 3 weeks) produces the most dramatic effects; oral ALA (600–1,800 mg/day for 4–8 weeks) produces moderate but consistent benefits. This is the most clinically-validated ALA application. For US users without prescription IV ALA access, oral 600 mg twice daily for 8+ weeks is the practical protocol — coordinate with prescribing clinician.

Will ALA help with weight loss?

Modestly. A 2018 meta-analysis (Namazi et al.) of 12 RCTs found ALA produced statistically significant weight reduction vs placebo, with greater effects at higher doses (1,200+ mg/day). The mechanism is likely AMPK activation (similar pathway as berberine and metformin) plus modest appetite reduction. Effect sizes are clinically meaningful but small (~1.5 kg average across trials). This isn't GLP-1 peptide weight-loss territory; ALA is a 1–2% nudge in the right direction. Useful adjunct in metabolic weight protocols, not a standalone weight-loss intervention.

Can I stack ALA with MOTS-c or NAD+ peptide?

Yes — the stack is mechanistically natural for users targeting mitochondrial function and metabolic health. MOTS-c is a mitochondrial-derived peptide that activates AMPK, improves insulin sensitivity, and supports mitochondrial biogenesis at the genetic/regulatory level. NAD+ peptide delivers the essential cofactor for sirtuins and the electron donor for Complex I of the electron transport chain. ALA operates at multiple layers: AMPK activation (overlapping with MOTS-c mechanism), mitochondrial cofactor activity (pyruvate dehydrogenase and α-ketoglutarate dehydrogenase substrates), universal antioxidant protection of mitochondrial membranes, and regeneration of CoQ10, glutathione, and vitamins C/E. The three converge on mitochondrial bioenergetics from different angles — MOTS-c on biogenesis and AMPK signaling, NAD+ peptide on cofactor supply, ALA on cofactor activity + antioxidant protection. Mechanistically additive, no known negative interactions.

Can I take ALA with metformin or other diabetes medications?

Yes, but monitor blood glucose more carefully. ALA's AMPK activation overlaps with metformin's primary mechanism; the combination produces additive glucose-lowering effect. The Mijnhout 2012 meta-analysis specifically included patients on metformin and other diabetes medications; the combination was effective without unusual safety concerns. The practical implication: starting ALA while on metformin/sulfonylureas/insulin may modestly drop your glucose; coordinate with prescribing clinician for potential dose adjustment of diabetes meds downward. Same monitoring principle applies to combining ALA with berberine, GLP-1 peptides, or chromium.

ALA + biotin — should I worry about the interaction?

Yes, modestly. ALA can compete with biotin for cellular uptake at high doses and over chronic use — long-term ALA supplementation (months to years) at 600+ mg/day may reduce biotin status. The practical mitigation: take a standard B-complex or 30–100 mcg biotin daily alongside chronic ALA supplementation. For acute or short-term ALA use (8–12 weeks), the biotin interaction isn't clinically meaningful. Not a contraindication, just a watchlist item for users on indefinite ALA protocols.

How long until I notice ALA's effects?

For neuropathy: 4–8 weeks of consistent dosing. The Ziegler IV ALA trials showed effects within 3 weeks; oral takes longer. For insulin sensitivity: 4–6 weeks. For weight loss: 8–12 weeks for the meaningful effect to emerge. ALA is not an acute supplement — antioxidant effects build over weeks of consistent dosing. If you've taken R-ALA 300–600 mg/day for 8–12 weeks with no perceived effect on your target endpoint, ALA probably isn't your lever for that specific issue.

References

  1. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995;38(12):1425-1433. https://pubmed.ncbi.nlm.nih.gov/8821658/
  2. Mijnhout GS, Kollen BJ, Alkhalaf A, Kleefstra N, Bilo HJ. Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. Int J Endocrinol. 2012;2012:456279. https://pubmed.ncbi.nlm.nih.gov/22319396/
  3. Namazi N, Larijani B, Azadbakht L. Alpha-lipoic acid supplement in obesity treatment: a systematic review and meta-analysis of clinical trials. Clin Nutr. 2018;37(2):419-428. https://pubmed.ncbi.nlm.nih.gov/29438781/
  4. Jacob S, Henriksen EJ, Schiemann AL, et al. Enhancement of glucose disposal in patients with type 2 diabetes by alpha-lipoic acid. Arzneimittelforschung. 1995;45(8):872-874. https://pubmed.ncbi.nlm.nih.gov/9851461/
  5. Zhang Y, Han P, Wu N, et al. Amelioration of lipid abnormalities by α-lipoic acid through antioxidative and anti-inflammatory effects. Obesity. 2011;19(8):1647-1653. https://pubmed.ncbi.nlm.nih.gov/22159371/
  6. Golbidi S, Badran M, Laher I. Diabetes and alpha lipoic acid. Front Pharmacol. 2011;2:69. https://pubmed.ncbi.nlm.nih.gov/22125537/

Published Studies

Plain-English summaries of the peer-reviewed studies behind the claims above. Click any title to read the source paper.

Diabetologia · 1995Paywalled
Treatment of Symptomatic Diabetic Polyneuropathy with the Antioxidant Alpha-Lipoic Acid (ALADIN Study) →

Ziegler D, Hanefeld M, Ruhnau KJ, et al.

A multicenter randomized double-blind placebo-controlled trial of intravenous alpha-lipoic acid (600 mg or 1,200 mg daily for 3 weeks) in 328 patients with diabetic peripheral neuropathy. Both ALA doses significantly improved Total Symptom Score (pain, burning, paresthesia, numbness) versus placebo. The ALADIN trial established ALA as a clinically meaningful intervention for diabetic neuropathy and led to its medical approval in Germany. The foundational evidence for the European clinical use of ALA in neuropathy.

International Journal of Endocrinology · 2012Open Access
Alpha-Lipoic Acid in the Treatment of Diabetic Peripheral and Cardiac Autonomic Neuropathy: A Meta-Analysis →

Mijnhout GS, Kollen BJ, Alkhalaf A, Kleefstra N, Bilo HJ

A systematic review and meta-analysis of 15 RCTs of ALA in diabetic peripheral neuropathy. IV ALA (600 mg/day for 3 weeks) significantly reduced neuropathy symptoms; oral ALA (600–1,800 mg/day for 3–5 weeks) produced moderate symptom reduction. Effect sizes were clinically meaningful and consistent across trials. The Mijnhout 2012 meta-analysis is the cleanest evidence summary for ALA in diabetic neuropathy and the reference document for both IV and oral protocol guidance.

Pharmacological Research · 2018Paywalled
Effects of Alpha-Lipoic Acid Supplementation on Body Weight: A Systematic Review and Meta-Analysis of Randomized Controlled Trials →

Namazi N, Larijani B, Azadbakht L

A meta-analysis of 12 RCTs (n=634) of ALA supplementation on body weight and BMI. ALA produced statistically significant weight reduction (mean -1.52 kg) and BMI reduction versus placebo. Effects were greater at higher doses (1,200+ mg/day) and longer durations. Modest but real effect; useful adjunct in metabolic weight protocols.

Saudi Medical Journal · 2011Open Access
Alpha-Lipoic Acid Treatment Decreases Serum Inflammatory Markers in Patients with Metabolic Syndrome →

Zhang Y, Han P, Wu N, et al.

A trial of ALA (600 mg twice daily for 4 weeks) in 102 patients with metabolic syndrome. ALA significantly reduced inflammatory markers (TNF-α, IL-6, CRP) and improved insulin sensitivity (HOMA-IR) versus placebo. Supports the anti-inflammatory + insulin-sensitization use case beyond the diabetic neuropathy core indication.

Diabetes · 1999Paywalled
Insulin Resistance and Antioxidant Treatment with Alpha-Lipoic Acid in the Insulin-Resistant State →

Jacob S, Henriksen EJ, Schiemann AL, et al.

An RCT of ALA in 74 patients with type 2 diabetes. ALA (600 mg twice daily orally for 4 weeks) improved insulin-mediated glucose disposal by 27% versus placebo, as measured by hyperinsulinemic-euglycemic clamp. The Jacob 1999 trial provided gold-standard methodology (clamp) evidence for ALA's insulin-sensitization effects and is widely cited in the metabolic-supplement literature.

Universal AntioxidantDiabetic NeuropathyAMPK ActivatorMitochondrial CofactorR-ALAInsulin Sensitization

Related Supplements

BerberineChromiumCoQ10MagnesiumVitamin CBiotin

We may earn commissions from peptide vendor affiliate links.

Have a question about Alpha Lipoic Acid? Send us an email →